Management of agitated, violent or psychotic patients in the emergency department: An overdue protocol for an increasing problem;Atención al paciente agitado, violento o psicótico en urgencias: Un protocolo pendiente para una patología en aumento

Anales de Pediatria

Volumn 63, Issue 6, 2005, Pages 526-536

  Jimenez Busselo M T ^a   Arago Domingo J ^a   Nuno Ballesteros A ^a   Lono Capote J ^a   Ochando Perales, G ^a  

^a HOSPITAL INFANTIL LA FE   (Spain)

Author keywords

Chemical restraint; Children; Emergency department; Physical restraint; Psychomotor agitation; Psychotic disorder; Violent behavior

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; COCAINE; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; ILLICIT DRUG; LORAZEPAM; LOXAPINE; LYSERGIDE; MESORIDAZINE; MIDAZOLAM; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE;

ACUTE PSYCHOSIS; AGGRESSION; AGITATION; AKATHISIA; AKINESIA; BRADYCARDIA; CHILD; CHILD HEALTH CARE; CHILD PSYCHIATRY; CLINICAL PROTOCOL; DELIRIUM; DRUG CHOICE; DYSTONIA; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; IMMOBILIZATION; JUVENILE DELINQUENCY; OCULOGYRIC CRISIS; PSYCHOSOCIAL DISORDER; QT PROLONGATION; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; TORTICOLLIS; VIOLENCE;

EID: 33644841295     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1695-4033(05)70253-8     Document Type: Review

References (20)

1. Przybylo HJ, Martini DR, Mazurek AJ, Bracey E, Johnsen L, Cote CJ, et al. Assessing behavior in children emerging from anesthesia: can we apply psychiatric diagnostic techniques? Paediatr Anesth. 2003;13:609-16.
2. Yamashita M. Postanesthetic excitation and agitation. Paediatr Anesth. 2003;13:642-3.
3. Sorrentino A. Chemical restraints for the agitated, violent, or psychotic pediatric patient in the emergency department: controversies and recommendations. Curr Opin Pediatr. 2004;16: 201-5.
4. Dorfman DH, Kastner B. The use of restraint for pediatric psychiatric patients in emergency departments. Pediatr Emerg Care. 2004;20:151-6.
5. Liebelt EL. Therapeutics and toxicology issues associated with the agitated, violent, or psychotic pediatric patient. Curr Opin Pediat. 2004;16:199-200.
6. a ed. Madrid: Díaz de Santos: 1998. p. 261-5.
7. Lahoti SL, McClain N, Girardet R, McNeese M, Cheung K. Evaluating the child for sexual abuse. Am Family Physician. 2001; 63:883-92.
8. a ed. española. Ed. Harcourt; 1999. p. 1579-84.
9. a Edición: 21-31. Ed. Consellerías de Sanidad y Bienestar Social de la Generalitat Valenciana, 2002
10. Benitz WE, Tatro DS. Antipsychotics. En. The pediatric drug handbook. 3rd ed. St. Louis: Mosby Inc; 1995. p. 89-108.
11. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry. 1990;51 Suppl:41-6; discussion 50-3.
12. Gámez M, Irala Indart C. Selección de benzodiazepinas: bases para su utilización en el hospital. Farm Hosp. 1996;21:117-22.
13. Coté CJ. Sedation for the pediatric patient. Fed Clinics North Am. 1994;41:31-58.
14. Brown RL, Hence A, Greenhalgh DG, Warden GD. The use of Haloperidol in the agitated, critically ill pediatric patient with burns. J Burn Care Rehabil. 1996;17:34-8.
15. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997;15:335-40.
16. Bieniek SA, Ownby RL, Peǹalver A, Domínguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 1998;18:57-62.
17. Hill S, Petit J. Psychiatric Emergencies. The violent patient. Emerg Med Clin North Am. 2000;18:301-15.
18. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine, an up-dated review of its use in the management of schizofrenia. Drugs. 2001;61:111-61.
19. Roomana M. Sheikh, Khalid Ahmed. The efficacy of Olanzapine, as needed, to treat acute agitación in juveniles. J Child Adolesc Psychiatr. 2002;12:71-3.
20. Eli Lilly and Company. Briefing document for Olanzapina intramuscular, FDA Psychopharmacological Drugs Advisory Committee, January 11, 2001 with Addendum February 14, 2001. Disponible en: www.fda.gov